IAS

COFACE SA: FY-2023 results: net income at €240.5m and proposed dividend at €1.30 per share

Retrieved on: 
Tuesday, February 27, 2024
Investment, Growth, IAS, Metal, COVID, Policy, Employment, PPT, Annual, Environment, FX, Depreciation, Financial services

In North America, turnover increased +5.6% at constant FX and +2.1% as reported, driven by the return in client activity and rising commissions.

Key Points: 
  • In North America, turnover increased +5.6% at constant FX and +2.1% as reported, driven by the return in client activity and rising commissions.
  • The combined ratio net of reinsurance was 64.3% for the year, improved by 3.3 ppts year on year.
  • In total, net income (group share) stood at €240.5m, stable compared to 2022 under IFRS 17, of which €50.8m in Q4-23.
  • This change was mainly due to the positive net income of €240.5m, the payment of the dividend (-€227.0m) and the increase in unrealised capital gains (€25.0m).

Unblock Health and Health Gorilla Announce Collaboration to Enhance Patient Data Access through TEFCA

Retrieved on: 
Monday, February 26, 2024
Hospital, Emergency, Caregiver, Treatment, Public health, IAS, Common, Organization, Patient, PAB, Grace, CLEAR, Partnership, Nursing

Unblock Health will participate in Health Gorilla’s QHIN to enable patients to retrieve their personal health records under the Individual Access Services (IAS) purpose of use.

Key Points: 
  • Unblock Health will participate in Health Gorilla’s QHIN to enable patients to retrieve their personal health records under the Individual Access Services (IAS) purpose of use.
  • As a QHIN, Health Gorilla supports data exchange for multiple purposes of use, including Treatment, Payment, Health Care Operations, Public Health, Government Benefits Determination, and IAS.
  • Unblock Health is collaborating with Health Gorilla on IAS solutions to ensure that patients can seamlessly and securely access their data from a vast network of participating hospitals and clinics.
  • “We are proud to collaborate with Grace and the Unblock Health team, who have proven a relentless commitment to empowering patients through access to their health data.

Manifest MedEx Now Exchanging Real-Time Health Data Under the CalHHS Data Exchange Framework for Participants

Retrieved on: 
Thursday, March 7, 2024
Data Management, Technology, Health, Philanthropy, General Health, Healthcare Reform, Other Philanthropy, Health Technology, Health Insurance, Networks, Public Policy, Government, Caregiver, Audio signal processing, Directory, Charge density, Investment, Interoperability, IAS, ADT, AutoCAD, General number field sieve, Geography, SDOH, HIPAA, Element, Organization, SOGI, HITRUST, Manifest, Accountability Act, Nursing

Manifest MedEx (MX), the largest nonprofit qualified health information organization (QHIO) for the CalHHS Data Exchange Framework (DxF), announced today it is securely exchanging permitted health data in real time on behalf of DxF participants, including with other QHIOs, marking a new milestone in the implementation of the DxF.

Key Points: 
  • Manifest MedEx (MX), the largest nonprofit qualified health information organization (QHIO) for the CalHHS Data Exchange Framework (DxF), announced today it is securely exchanging permitted health data in real time on behalf of DxF participants, including with other QHIOs, marking a new milestone in the implementation of the DxF.
  • The nearly 200 organizations that selected Manifest MedEx as their data exchange intermediary in the DxF Participant Directory are now successfully meeting their health data sharing obligations under AB 133, state law that requires most healthcare entities in California to exchange health and social services information beginning this year.
  • In addition to clinical information from providers’ electronic health record systems, Manifest Medex shares DxF-required administrative health data from payers, including adjudicated claims and encounters from health insurers and health plans.
  • Organizations interested in using Manifest MedEx as their DxF intermediary should reach out to Manifest MedEx at [email protected] and ensure they have updated their organization listing in the DxF Participant Directory.

Cencosud Reports 2023 Revenue Growth of 0.2%

Retrieved on: 
Wednesday, March 6, 2024
Finance, Food, Beverage, Retail, Professional Services, Supermarket, Adjustment, S.A, Growth, IAS, CLP, Weather, GLA

This reflects the negative impact of the hyperinflation accounting adjustment in Argentina (IAS 29) and a challenging macroeconomic environment, resulting in lower consumption and growth in the countries where Cencosud operates.

Key Points: 
  • This reflects the negative impact of the hyperinflation accounting adjustment in Argentina (IAS 29) and a challenging macroeconomic environment, resulting in lower consumption and growth in the countries where Cencosud operates.
  • "2023 was a year marked by a challenging macroeconomic environment in the countries in which Cencosud operates.
  • Despite this, Cencosud reported slight growth in revenues and maintained a double-digit EBITDA margin, which is the result of a strategy focused on financial strengthening, profitable growth, and the consolidation of our digital ecosystem," commented Rodrigo Larraín, CEO of Cencosud.
  • Cencosud will invest US$641 million in 2024, focusing on accelerating organic growth and innovation, strengthening the physical-digital ecosystem, and achieving greater operational efficiencies and profitability.

World View Secures Strategic Series D Funding Led by SNC

Retrieved on: 
Tuesday, February 27, 2024
Public Policy, Government, Defense, Other Defense, Finance, Professional Services, Homeland Security, Aerospace, Manufacturing, HAP, NOAA, Multimedia, United States Air Force, SNC, NASA, ISR, Aviation, IAS, Series, Boeing, Worldview, Security, Altitude, Partnership, Management

World View, a global leader in stratospheric exploration and flight, announces the successful opening and initial funding of a Series D round.

Key Points: 
  • World View, a global leader in stratospheric exploration and flight, announces the successful opening and initial funding of a Series D round.
  • (Photo: Business Wire)
    This strategic investment builds upon the multi-year strategic partnership initiated in 2022 between World View and SNC.
  • As part of the Series D funding round, two notable individuals join the World View Board of Directors.
  • “SNC is committed to quality and excellence in performance, and we look forward to enhancing this much-needed capability in coordination with World View."

The Honorable Peter J. O’Donoghue (Ret.) Joins NAM’s Esteemed Panel of Neutrals

Retrieved on: 
Tuesday, February 20, 2024
Communications, Legal, Professional Services, Public Relations, Investor Relations, RET, National Arbitration and Mediation, The Honourable, Retirement, IAS, Criminal court, Mediation, Supreme court, Justice, Practice of law

NAM (National Arbitration and Mediation) is proud to announce the addition of the Honorable Peter J. O’Donoghue (Ret.)

Key Points: 
  • NAM (National Arbitration and Mediation) is proud to announce the addition of the Honorable Peter J. O’Donoghue (Ret.)
  • The Honorable Peter J. O'Donoghue's remarkable judicial career includes 27 years spent as a Justice of the Supreme Court in Queens County, 15 of which were in the Medical Malpractice Part.
  • From 2008 until his retirement, all medical and dental malpractice filings in the Queens County courthouse were exclusively assigned to him.
  • Judge O'Donoghue conferenced, negotiated, mediated, and settled more than 300 medical malpractice matters each year while on the bench.

BioVaxys Technology Corp. Granted Voluntary Management Cease Trade Order

Retrieved on: 
Friday, March 8, 2024
CFO, Acquisition, Certification, Fortnight, Requirement, News, File, FRA, IAS, Ontario Securities Commission, OSC, DMCL, Documentation, IMV, National Policy, National instrument, IAS 10

VANCOUVER, BC, March 8, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced that the Ontario Securities Commission (the "OSC"), as the Company's principal regulator, on February 29, 2024, granted the Company's previously announced application for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").

Key Points: 
  • VANCOUVER, BC, March 8, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced that the Ontario Securities Commission (the "OSC"), as the Company's principal regulator, on February 29, 2024, granted the Company's previously announced application for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").
  • The management cease trade order is to remain in place until two full business days after the Company files the Required Reports and restricts all trading by James Passin, director, CEO and CFO of the Company in securities of the Company.
  • The Company applied for a management cease trade order as an alternative to the imposition by the OSC of a full cease trade order.
  • The management cease trade order prevents the officers and/or directors named in the order from trading in the Company's securities but does not affect the ability of other shareholders, including the public, to trade in securities of the Company.

BioVaxys Technology Corp. Granted Voluntary Management Cease Trade Order

Retrieved on: 
Wednesday, March 6, 2024
CFO, Acquisition, Certification, Fortnight, Requirement, News, File, FRA, IAS, Ontario Securities Commission, OSC, DMCL, Documentation, IMV, National Policy, National instrument, IAS 10

VANCOUVER, BC, March 6, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced that the Ontario Securities Commission (the "OSC"), as the Company's principal regulator, on February 29, 2024, granted the Company's previously announced application for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").

Key Points: 
  • VANCOUVER, BC, March 6, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced that the Ontario Securities Commission (the "OSC"), as the Company's principal regulator, on February 29, 2024, granted the Company's previously announced application for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").
  • The management cease trade order is to remain in place until two full business days after the Company files the Required Reports and restricts all trading by James Passin, director, CEO and CFO of the Company in securities of the Company.
  • The Company applied for a management cease trade order as an alternative to the imposition by the OSC of a full cease trade order.
  • The management cease trade order prevents the officers and/or directors named in the order from trading in the Company's securities but does not affect the ability of other shareholders, including the public, to trade in securities of the Company.

BioVaxys Technology Corp. Granted Voluntary Management Cease Trade Order

Retrieved on: 
Friday, March 8, 2024
CFO, Acquisition, Certification, Fortnight, Requirement, News, File, FRA, IAS, Ontario Securities Commission, OSC, DMCL, Documentation, IMV, National Policy, National instrument, IAS 10

VANCOUVER, BC, March 8, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced that the Ontario Securities Commission (the "OSC"), as the Company's principal regulator, on February 29, 2024, granted the Company's previously announced application for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").

Key Points: 
  • VANCOUVER, BC, March 8, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced that the Ontario Securities Commission (the "OSC"), as the Company's principal regulator, on February 29, 2024, granted the Company's previously announced application for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").
  • The management cease trade order is to remain in place until two full business days after the Company files the Required Reports and restricts all trading by James Passin, director, CEO and CFO of the Company in securities of the Company.
  • The Company applied for a management cease trade order as an alternative to the imposition by the OSC of a full cease trade order.
  • The management cease trade order prevents the officers and/or directors named in the order from trading in the Company's securities but does not affect the ability of other shareholders, including the public, to trade in securities of the Company.

IAS Expands "Made for Advertising" (MFA) AI-Driven Measurement and Optimization Solution with Industry-First Ad Clutter Detection and Avoidance Innovation

Retrieved on: 
Tuesday, March 5, 2024
Integral Ad Science, MFA, ANA, IAS, Advertising, Claudia Brant, Metadata, Ecosystem, Textile

NEW YORK, March 5, 2024 /PRNewswire/ -- Integral Ad Science (Nasdaq: IAS), a leading global media measurement and optimization platform, today announced the expansion of its Made for Advertising (MFA) AI-driven solution. With this enhancement, IAS now provides advertisers the first solution that can measure and optimize against both MFA and Ad Clutter sites to drive maximum efficacy across the programmatic buying process.

Key Points: 
  • With this enhancement, IAS now provides advertisers the first solution that can measure and optimize against both MFA and Ad Clutter sites to drive maximum efficacy across the programmatic buying process.
  • spam sites, or ad farms) created solely to serve ads, whereas Ad Clutter sites feature high ad density and high ad-to-content ratio, leading to lower performance.
  • As opposed to a static exclusion list, IAS uses advanced machine learning technology and additional signals built into IAS's core platform to intelligently identify MFA and Ad Clutter sites.
  • IAS's MFA AI-driven site Measurement and Optimization solution expands on the beta announced in Q4 2023 and will be available globally beginning in Q2 2024.